Vasoconstrictor cannabinoid analogs
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 19, 2006
Grant Date -
Nov 25, 2004
app pub date -
Aug 14, 2002
filing date -
Aug 15, 2001
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising: ##STR00001## wherein dashed lines independently represent either a single or a double bond, R.sub.1 is a lower alkyl, R.sub.2 is a lower alkyl, R.sub.3 is a lower alkyl or halogen, R.sub.4 is a lower alkyl or hydrogen, R.sub.5 is a lower alkyl or hydrogen, R.sub.6 is a hydrogen, lower alkyl or halogen, and R.sub.7 is a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully